Production of Therapeutic Enzymes by Lentivirus Transgenesis
- PMID: 31482493
- DOI: 10.1007/978-981-13-7709-9_2
Production of Therapeutic Enzymes by Lentivirus Transgenesis
Abstract
Since ERT for several LSDs treatment has emerged at the beginning of the 1980s with Orphan Drug approval, patients' expectancy and life quality have been improved. Most LSDs treatment are based on the replaced of mutated or deficient protein with the natural or recombinant protein.One of the main ERT drawback is the high drug prices. Therefore, different strategies trying to optimize the global ERT biotherapeutic production have been proposed. LVs, a gene delivery tool, can be proposed as an alternative method to generate stable cell lines in manufacturing of recombinant proteins. Since LVs have been used in human gene therapy, clinical trials, safety testing assays and procedures have been developed. Moreover, one of the main advantages of LVs strategy to obtain manufacturing cell line is the short period required as well as the high protein levels achieved.In this chapter, we will focus on LVs as a recombinant protein production platform and we will present a case study that employs LVs to express in a manufacturing cell line, alpha-Galactosidase A (rhαGAL), which is used as ERT for Fabry disease treatment.
Keywords: ERT; Fabry disease; LSDs; Lentiviral Vectors (LVs); rhαGAL.
Similar articles
-
High yield process for the production of active human α-galactosidase a in CHO-K1 cells through lentivirus transgenesis.Biotechnol Prog. 2017 Sep;33(5):1334-1345. doi: 10.1002/btpr.2538. Epub 2017 Sep 4. Biotechnol Prog. 2017. PMID: 28840666
-
Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.J Biomed Sci. 2010 Apr 16;17(1):26. doi: 10.1186/1423-0127-17-26. J Biomed Sci. 2010. PMID: 20398385 Free PMC article.
-
Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.J Cardiol. 2011 Jan;57(1):115-22. doi: 10.1016/j.jjcc.2010.08.003. Epub 2010 Sep 16. J Cardiol. 2011. PMID: 20846825
-
The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.Mol Genet Metab. 2019 Mar;126(3):212-223. doi: 10.1016/j.ymgme.2018.04.007. Epub 2018 Apr 26. Mol Genet Metab. 2019. PMID: 29785937
-
Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 May;13(3):e1684. doi: 10.1002/wnan.1684. Epub 2020 Dec 13. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021. PMID: 33314628 Review.
Cited by
-
Recombinant vaccines in 2022: a perspective from the cell factory.Microb Cell Fact. 2022 Oct 5;21(1):203. doi: 10.1186/s12934-022-01929-8. Microb Cell Fact. 2022. PMID: 36199085 Free PMC article. Review.
-
High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines.Vaccines (Basel). 2020 Aug 21;8(3):462. doi: 10.3390/vaccines8030462. Vaccines (Basel). 2020. PMID: 32825605 Free PMC article.
-
Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine.Front Aging Neurosci. 2020 Jan 31;12:4. doi: 10.3389/fnagi.2020.00004. eCollection 2020. Front Aging Neurosci. 2020. PMID: 32076403 Free PMC article.
References
-
- Bandaranayake AD, Almo SC (2014) Recent advances in mammalian protein production. FEBS Lett 588(2):253–260 - PubMed
-
- Baranyi L, Roy A, Embree HD, Dropulic B (2010) Lentiviral vector-mediated genetic modification of cell substrates for the manufacture of proteins and other biologics. PDA J Pharm Sci Technol 64:379–385 - PubMed
-
- Bennett LL, Mohan D (2013) Gaucher disease and its treatment options. Ann Pharmacother 47(9):1182–93
-
- Braulke T, Bonifacino JS (2009) Sorting of lysosomal proteins. BBA – Mol Cell Res 1793:605–614
-
- Braunlin E, Rosenfeld H, Kampmann C et al (2013) Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. J Inherit Metab Dis 36(2):385–394 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources